Although some studies included in this meta-analysis opted to compare the effects of SGLT-2 inhibitors with standard treatments not known to have any effects on NAFLD, some used pioglitazone50 or liraglutide51 as its control, which may slightly affect the positive magnitude of the results. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.